Interferon-α for TP53-mutated blood cancer after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a certain type of blood cancer (MDS or AML with a TP53 gene change) and have had a stem cell transplant.
- You must be between 12 and 65 years old.
- You should be in fairly good health after transplant, with no severe graft-versus-host disease or major organ problems.
- Your blood counts and kidney/heart function need to meet certain minimum levels.
- You cannot have other cancers needing treatment or severe infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.